Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Neuroinflammation and Neurodegeneration Mechanisms, T-cell and B-cell Immunology, and Immunotherapy and Immune Responses.
In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis
Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis.
Choroid plexus enlargement associates with serum neurofilament and predicts relapse-free progression in multiple sclerosis
CSF Proteins Associated With Neuroaxonal Damage in Early Active Multiple Sclerosis.
A disease-specific convergence of host and Epstein–Barr virus genetics in multiple sclerosis
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
Increased Disability Progression in rs10191329<sup>AA</sup> Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.
Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosis
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study).
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis
Glial Fibrillary Acid Protein Reflects Disease Activity in Autoimmune Encephalitis
Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis.
Biomarker combinations from different modalities predict early disability accumulation in multiple sclerosis.
GWAS highlights the neuronal contribution to multiple sclerosis susceptibility
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.
Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis
AMPAR inhibition lowers S1P in human blood and improves murine autoimmune neuroinflammation by blocking T cell egress from lymph nodes
Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases
Prognostic value of blood-based biomarkers in multiple sclerosis patients in the absence of clinical relapses or new MRI lesions.
Atypical adverse events in a real-world study of long-term immunomodulation for multiple sclerosis and neuromyelitis optica spectrum disorder.
Bruton's tyrosine kinase inhibitors rescue neuronal impairment caused by B cell-mediated lymphotoxin-α release.
Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.
AMPAR inhibition lowers S1P in human blood and improves murine autoimmune neuroinflammation by blocking T cell egress from lymph nodes.
Genetic Risk Variants for Multiple Sclerosis and Other Loci Linked to Intrathecal Immunoglobulin G Synthesis.